NCT00133003View on ClinicalTrials.gov

Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

PHASE4CompletedINTERVENTIONAL
Enrollment

2,022

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Coronary DiseaseAngina, Unstable
Interventions
DRUG

Abciximab

0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight

DRUG

Placebo

Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight

Trial Locations (5)

3435

St. Antonius Ziekenhuis Hospital, Nieuwegein

79189

Herz-Zentrum, Bad Krozingen

80636

Deutsches Herzzentrum Muenchen, Munich

81675

First Medizinische Klinik, Klinikum rechts der Isar, Munich

500-04012180

Instituto Dante Pazzanese de Cardiologia, São Paulo

All Listed Sponsors
collaborator

Technical University of Munich

OTHER

lead

Deutsches Herzzentrum Muenchen

OTHER

NCT00133003 - Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) | Biotech Hunter | Biotech Hunter